慢性化脓性中耳炎和中耳胆脂瘤病原学及药物敏感性临床对比分析OA
Pathogenic bacteria and drug sensitivity in patients with chronic suppurative otitis media and middle ear cholesteatoma
目的 针对慢性化脓性中耳炎(chronic suppurative otitis media,CSOM)与中耳胆脂瘤患者,建立围手术期抗生素选择策略.方法 纳入2023年1月至12月西南医科大学附属医院收治的80例CSOM及179例中耳胆脂瘤手术患者.其中,CSOM患者中男性27例(27耳),女性53例(53耳),年龄5~71岁,平均年龄(43.5±15.2)岁;中耳胆脂瘤患者中男性96例(96耳),女性83例(83耳),年龄3~83岁,平均年龄(42.1±18.8)岁.均于术前24 h无菌采集耳道分泌物样本,经纸片扩散法对比两组病原菌构成与抗菌药物敏感性差异.并将其按年龄分为未成年组、青年组、中年组和老年组进行对比分析.结果 (1)CSOM和中耳胆脂瘤病原菌检出率分别为50%和49.7%.(2)CSOM中检出率为革兰阳性菌56%、革兰阴性菌36%、真菌8%;中耳胆脂瘤中检出率为革兰阳性菌49%、革兰阴性菌44%、真菌7%.(3)CSOM和中耳胆脂瘤常见致病菌为金黄色葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌、表皮葡萄球菌.(4)金黄色葡萄球菌对达托霉素等抗菌药物敏感,对氨苄西林等药物存在较高耐药性.铜绿假单胞菌对哌拉西林/他唑巴坦等敏感,对环丙沙星等药物出现不同程度耐药.CSOM中铜绿假单胞菌对氨曲南耐药性显著高于中耳胆脂瘤组(P<0.05).(5)CSOM未成年组病原菌检出率最高(100%),其他组在45%~50%;中耳胆脂瘤中年组病原菌检出率最低(35.9%),显著低于青年组(P<0.05).CSOM患者以革兰阳性菌为主;中耳胆脂瘤仅青年组以革兰阳性菌为主,其他组以革兰阴性菌为主.(6)CSOM未成年组和老年组,中耳胆脂瘤未成年组和中年组常见致病菌均为金黄色葡萄球菌.结论 CSOM和中耳胆脂瘤主要病原菌是金黄色葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌和表皮葡萄球菌.不同年龄CSOM和中耳胆脂瘤病原菌检出率和常见致病菌不同.CSOM和中耳胆脂瘤病原菌药物敏感性存在差异.
Objective To develop evidence-based perioperative antibiotic selection strategies for patients with chronic suppurative otitis media(CSOM)and cholesteatoma of middle ear in Southwest China.Methods A total of 80 patients with CSOM and 179 patients with cholesteatoma of middle ear who underwent surgery at the Affiliated Hospital of Southwest Medical University from January to December 2023 were enrolled.The CSOM group included 27 males(27 ears)and 53 females(53 ears),aged 5 to 71 years(mean=43.5±15.2 years).The cholesteatoma group included 96 males(96 ears)and 83 females(83 ears),aged 3 to 83 years(mean=42.1±18.8 years).External auditory canal secretions were collected 24 hours before surgery.Pathogenic bacteria and antibiotic susceptibility profiles were compared between the two groups using the Kirby-Bauer method.Patients were further stratified into underage,young,middle-aged,and elderly groups for age based analysis.Results(1)Pathogen detection rates were 50%in the CSOM group and 49.7%in the cholesteatoma group,respectively.(2)In the CSOM group,Gram-positive bacteria were detected in 56%,Gram-negative bacteria in 36%,and fungi in 8%of cases,whereas in the cholesteatoma group,the corresponding rates were 49%,44%and 7%.(3)The predominant pathogens in both diseases were Staphylococcus aureus,Pseudomonas aeruginosa,Acinetobacter baumannii and Staphylococcus epidermidis.(4)Staphylococcus aureus showed high susceptibility to antimicrobiotics such as daptomycin,but high resistance to drugs such as ampicillin.Pseudomonas aeruginosa was susceptible to agents such as piperacillin/tazobactam,but showed variable resistance to drugs such as ciprofloxacin.Notably,resistance to aztreonam was significantly higher in Pseudomonas.aeruginosa in the CSOM group than in the cholesteatoma group(P<0.05).(5)In CSOM,detection of pathogens reached 100%in the underage group,but was at 45%to 50%in the other age groups.In cholesteatoma,the middle-aged group had the lowest detection rate(35.9%),significantly lower than that in the young adult group(P<0.05).Gram-positive bacteria predominated across all groups in CSOM.In cholesteatoma,Gram-positive bacteria predominated only in the young group,with Gram-negative bacteria predominating in the other age groups.(6)Staphylococcus aureus was the predominant pathogen in the underage and elderly groups in CSOM,as well as in the underage and middle-aged groups in cholesteatoma.Conclusions Staphylococcus aureus,Pseudomonas aeruginosa,Acinetobacter baumannii,and Staphylococcus epidermidis were the major pathogens in both CSOM and middle ear cholesteatoma.Pathogen detection rates and profiles varied across age.
刘淑云;邱燕;房海旭;陈媛慧;钟书怡;常蓝尹;杨烨;殷泽登
西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000西南医科大学生物化学教研室,泸州 646000西南医科大学附属医院耳鼻咽喉头颈外科,泸州 646000
慢性化脓性中耳炎中耳胆脂瘤病原菌药物敏感性实验
chronic suppurative otitis mediacholesteatoma of middle earpathogenic bacteriadrug susceptibility test
《中华耳科学杂志》 2026 (5)
436-442,7
四川省自然科学基金项目(2023NSFSC1448)四川省科技计划联合创新专项(2022YFS0629-C3)泸州市人民政府西南医科大学科技战略合作项目(2024LZXNYDJ075)
评论